American infectious disease physician at Johns Hopkins Center for Health Security
Bloomberg reports a telehealth company has disclosed plans to sell already allowed compounds such as sermorelin and glutathione, which patients pursue for wellness benefits despite limited clinical evidence. The move underscores ongoing tensions between patient demand and scientific validation.